Full set of capabilities in Biotechnology
In 2007 Gedeon Richter together with Helm AG founded Richter-Helm Biologics Joint venture (JV) in Germany. The JV embraces state-of-the facilities specialised in
microbial cell fermentation technologies: FDA and EMA approved R&D laboratories in Hamburg, cGMP pilot plant capacities in Hannover and FDA and EMA approved drug substance manufacturing plant in Bovenau.
Gedeon Richter also has significant capacities in
mammalian cell fermentation based technologies. In 2007 the first mammalian cell development R&D laboratories and a cGMP pilot plant were established in the Company's Budapest site. In 2008 Richter launched a green-field investment to build a plant in Debrecen in order to create the conditions for the manufacturing of mammalian cell products at commercial scale. The drug substance and fill-and-finish manufacturing plants were put into service in 2012.
Thanks to these investments too, Gedeon Richter's activities in biotechnology encompass the
full in-house value chain, ranging from research and development through manufacturing to commercialization in key geographical areas.
Current biotechnology portfolio
|
Product |
Indication |
Status |
| BEMFOLA (biosimilar r-hFSH) | Infertility | Richter acquired the product in 2016, marketed in more than 30 countries |
| TERROSA (biosimilar teriparatide) | Postmenopausal osteoporosis | EU marketing authorization received in January 2017 |
| Pegfilgrastim | Neutropenia | Late stage clinical development |
| Rituximab | various forms of cancer and auto-immune diseases | Late stage clinical development |
| Trastuzumab | Certain forms of breast cancer and gastric cancer | Licensed-in and technology transfer development project |
Further 3 ongoing biosimilar projects in early stage |
Partnering with us
The Company's Biotechnology Business Unit has been continuously seeking new partnerships in order to:
-
Leverage R&D, manufacturing and commercialization skills via in-licensing and co-development & co-commercialization in Europe, CIS and Latin-America. Our areas of interest are:
- Oncology
- Osteoporosis
- Women's Healthcare
- Niche indications/orphans
-
Secure co-development and commercialization agreements for Gedeon Richter's biosimilar portfolio for the following geographic areas:
- USA & Canada
- Asia
- Australia and New Zealand
- MENA, Africa
Contact us
Dr. Johanna Knospe
Head of Biotechnology Business Development Department
E-mail:
knospej@richter.hu
Phone: +36-1-431-4928
Zsuzsanna Molnár
Senior Business Analyst, Biotechnology Business Development Department
E-mail:
zsmolnar@richter.hu
Phone: +36-1-889-8647
You can also meet us in person in the following congresses:
- ESMO, Madrid - September 8-12 , 2017
- CphI, Frankfurt - 24-26 October, 2017
- Bio Europe Fall, Berlin - November 6-8, 2017
- PLCD, Mainz - November 30 - December 1., 2017
